Galderma announces agreement for cosmetic tissue products

Galderma, the dermatology-based pharmaceutical company spawned from a collaboration between Nestle and L’Oreal, has agreed a development and commercialisation deal with Anika Therapeutics for cosmetic tissue augmentation (CTA) therapies.

Anika’s CTA therapies are used for a variety of dermatological procedures, from removing wrinkles and augmenting lips, to remediating scar tissue. Under the terms of the agreement, Galderma will pay Anika an upfront fee of $1 million (544,000 pounds), with further milestone payments, royalties and transfer payments for the supply of CTA therapies.

Galderma will also reimburse Anika with development costs for enhancing existing products, clinical trials and extensions to the product range. The enhanced CTA therapies are expected to be marketed from 2007.

Humberto C Antunes, Galderma’s chief executive officer, remarked: “We believe Anika’s know-how has tremendous potential to produce innovative solutions to currently unmet needs in Aesthetic Dermatology.”

“Galderma’s commitment to bring products to market worldwide reflects our long term commitment to continuously strive to meet the needs of dermatology patients,” he added.

Anika’s chief executive, Charles H Sherwood, concluded: “Galderma’s demonstrated marketing and distribution expertise and outstanding reputation for success has established them as one of the premier dermatological companies. We look forward to working together to meet the needs of patients.”

Galderma describes its self as the number one dermatological pharmaceutical company, designing treatments for skin, hair and nail diseases such as acne, psoriasis, hyperpigmentation disorders and non-melanoma skin cancers.

© Adfero Ltd